Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TransMedics Group, Inc.TMDX · Entity 4261 | Chief Commercial Officer | March 03, 2025 | March 05, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TransMedics Group, Inc.
Report date March 03, 2025 · Filed March 05, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,042 |
Reported balance
After 2025-03-03 transaction · row 1
1 source rowRow 1 · 2025-03-03 · Sale · Disposed 2,407 · Balance 36,042 F1: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction pursuant to the terms of the RSU award. |
Filing footnotes · ownership attribution and instrument terms
F1: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction pursuant to the terms of the RSU award.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 512 | $120.86 | $61,880.32 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 14 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,441 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F11 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $120.41 to $121.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,799 | $119.85 | $215,610.15 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 13 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,953 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F10 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $119.40 to $120.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,259 | $118.93 | $149,732.87 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 12 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,752 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $118.415 to $119.37, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 738 | $117.96 | $87,054.48 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 11 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,011 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $117.46 to $118.38, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 326 | $116.80 | $38,076.80 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 10 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,749 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $116.32 to $117.155, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 100 | $113.16 | $11,316.00 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 9 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,075 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 15,892 | $109.83 | $1,745,418.36 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 8 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,175 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $109.60 to $110.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 3,027 | $109.28 | $330,790.56 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 7 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,067 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $108.61 to $109.59, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 3,477 | $107.84 | $374,959.68 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 6 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,094 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.50 to $108.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 12,250 | $107.00 | $1,310,750.00 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 5 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,571 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.51 to $107.4775, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 23,231 | $105.96 | $2,461,556.76 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 4 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,821 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.50 to $106.455, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,083 | $13.28 | $14,382.24 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 3 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,052 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 1,458 | $38.46 | $56,074.68 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| May 01, 2024 Filed May 3, 2024 16:30 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 45,326 | $38.46 | $1,743,237.96 |
DisclosureSEC source: 0000950170-24-052962 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,511 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| May 01, 2024 Filed May 14, 2024 18:00 UTC Amendment | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 11,051 | $105.71 | $1,168,201.21 |
DisclosureSEC source: 0000950170-24-059829 · ownership.xml · nonDerivative · entry 14 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Indirect · By the Tamer Ibrahim Ahmed Khayal Trust Disclosed balance after: 0 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F14 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.50 to $105.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 14, 2024 18:00 UTC Amendment | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 100 | $123.66 | $12,366.00 |
DisclosureSEC source: 0000950170-24-059829 · ownership.xml · nonDerivative · entry 13 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,843 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F13 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $123.64 to $123.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 14, 2024 18:00 UTC Amendment | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 444 | $121.84 | $54,096.96 |
DisclosureSEC source: 0000950170-24-059829 · ownership.xml · nonDerivative · entry 12 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,943 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F12 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $121.515 to $122.505, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 14, 2024 18:00 UTC Amendment | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 422 | $121.21 | $51,150.62 |
DisclosureSEC source: 0000950170-24-059829 · ownership.xml · nonDerivative · entry 11 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,387 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F11 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $120.52 to $121.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 14, 2024 18:00 UTC Amendment | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,815 | $119.96 | $217,727.40 |
DisclosureSEC source: 0000950170-24-059829 · ownership.xml · nonDerivative · entry 10 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,809 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F10 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $119.51 to $120.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 14, 2024 18:00 UTC Amendment | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,417 | $119.00 | $168,623.00 |
DisclosureSEC source: 0000950170-24-059829 · ownership.xml · nonDerivative · entry 9 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,624 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F9 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $118.51 to $119.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 14, 2024 18:00 UTC Amendment | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 759 | $117.97 | $89,539.23 |
DisclosureSEC source: 0000950170-24-059829 · ownership.xml · nonDerivative · entry 8 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,041 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F8 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $117.46 to $118.425, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 14, 2024 18:00 UTC Amendment | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 326 | $116.80 | $38,076.80 |
DisclosureSEC source: 0000950170-24-059829 · ownership.xml · nonDerivative · entry 7 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,800 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F7 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $116.32 to $117.155, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 14, 2024 18:00 UTC Amendment | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 100 | $113.16 | $11,316.00 |
DisclosureSEC source: 0000950170-24-059829 · ownership.xml · nonDerivative · entry 6 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,126 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| May 01, 2024 Filed May 14, 2024 18:00 UTC Amendment | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 5,313 | $110.00 | $584,430.00 |
DisclosureSEC source: 0000950170-24-059829 · ownership.xml · nonDerivative · entry 5 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,226 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F6 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $110.00 to $110.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 14, 2024 18:00 UTC Amendment | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 13,078 | $109.68 | $1,434,395.04 |
DisclosureSEC source: 0000950170-24-059829 · ownership.xml · nonDerivative · entry 4 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,539 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $109.00 to $109.855, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 14, 2024 18:00 UTC Amendment | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,792 | $108.35 | $194,163.20 |
DisclosureSEC source: 0000950170-24-059829 · ownership.xml · nonDerivative · entry 3 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,617 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $107.89 to $108.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 14, 2024 18:00 UTC Amendment | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 11,789 | $107.20 | $1,263,780.80 |
DisclosureSEC source: 0000950170-24-059829 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,409 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $106.885 to $107.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 01, 2024 Filed May 14, 2024 18:00 UTC Amendment | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 14,854 | $106.25 | $1,578,237.50 |
DisclosureSEC source: 0000950170-24-059829 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,198 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $105.89 to $106.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 17:19 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,171 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0000950170-24-043432 · ownership.xml · derivative · entry 11 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 61,368 Underlying: Common Stock · 7,171 shares Expires 2031-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F6 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on the fourth anniversary of the vesting commencement date, February 24, 2021. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 17:19 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,341 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000950170-24-043432 · ownership.xml · derivative · entry 10 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,341 shares Expires 2030-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · derivative.exercise_date: The option is fully vested. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 17:19 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 4,980 | $91.11 | $453,727.80 |
DisclosureSEC source: 0000950170-24-043432 · ownership.xml · nonDerivative · entry 6 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,185 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $91.00 to $91.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 17:19 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 10,532 | $90.14 | $949,354.48 |
DisclosureSEC source: 0000950170-24-043432 · ownership.xml · nonDerivative · entry 5 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,165 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $90.00 to $90.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 17:19 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 7,171 | $38.46 | $275,796.66 |
DisclosureSEC source: 0000950170-24-043432 · ownership.xml · nonDerivative · entry 4 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 17:19 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 8,341 | $16.14 | $134,623.74 |
DisclosureSEC source: 0000950170-24-043432 · ownership.xml · nonDerivative · entry 3 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 17:19 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,388 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000950170-24-043432 · ownership.xml · derivative · entry 9 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,341 Underlying: Common Stock · 4,388 shares Expires 2030-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · derivative.exercise_date: The option is fully vested. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 17:19 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 4,388 | $90.00 | $394,920.00 |
DisclosureSEC source: 0000950170-24-043432 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,185 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $90.00 to $90.025, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 17:19 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 4,388 | $16.14 | $70,822.32 |
DisclosureSEC source: 0000950170-24-043432 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| April 04, 2024 Filed Apr 5, 2024 16:58 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,917 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000950170-24-042335 · ownership.xml · derivative · entry 10 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,729 Underlying: Common Stock · 2,917 shares Expires 2030-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F5 · derivative.exercise_date: The option is fully vested. Read SEC document |
| April 04, 2024 Filed Apr 5, 2024 16:58 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,030 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-042335 · ownership.xml · derivative · entry 9 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,917 Underlying: Common Stock · 2,030 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| April 04, 2024 Filed Apr 5, 2024 16:58 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 4,947 | $80.36 | $397,540.92 |
DisclosureSEC source: 0000950170-24-042335 · ownership.xml · nonDerivative · entry 5 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,185 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $80.00 to $80.675, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 04, 2024 Filed Apr 5, 2024 16:58 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 2,917 | $16.14 | $47,080.38 |
DisclosureSEC source: 0000950170-24-042335 · ownership.xml · nonDerivative · entry 4 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,132 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| April 04, 2024 Filed Apr 5, 2024 16:58 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 2,030 | $13.28 | $26,958.40 |
DisclosureSEC source: 0000950170-24-042335 · ownership.xml · nonDerivative · entry 3 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:58 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,053 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-042335 · ownership.xml · derivative · entry 8 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,947 Underlying: Common Stock · 5,053 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F4 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:58 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 5,053 | $80.06 | $404,543.18 |
DisclosureSEC source: 0000950170-24-042335 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,185 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $80.00 to $80.205, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 03, 2024 Filed Apr 5, 2024 16:58 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 5,053 | $13.28 | $67,103.84 |
DisclosureSEC source: 0000950170-24-042335 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,238 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 19:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $16.14 | $0.00 |
DisclosureSEC source: 0000950170-24-030277 · ownership.xml · derivative · entry 6 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,646 Underlying: Common Stock · 100 shares Expires 2030-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 19:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 1,317 | $87.63 | $115,408.71 |
DisclosureSEC source: 0000950170-24-030277 · ownership.xml · nonDerivative · entry 3 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,185 F2 · kind: Required number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale was made to satisfy tax withholding obligations through a "sell to cover" transaction pursuant to the terms of the RSU award. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 19:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | SaleCommon Stock | 100 | $90.04 | $9,004.00 |
DisclosureSEC source: 0000950170-24-030277 · ownership.xml · nonDerivative · entry 2 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,502 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| March 08, 2024 Filed Mar 12, 2024 19:31 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionCommon Stock | 100 | $16.14 | $1,614.00 |
DisclosureSEC source: 0000950170-24-030277 · ownership.xml · nonDerivative · entry 1 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 18:28 UTC | TransMedics Group, Inc. TMDX · Entity 4261 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $13.28 | $0.00 |
DisclosureSEC source: 0000950170-24-026492 · ownership.xml · derivative · entry 9 Khayal Tamer I · CIK 0001430462 · Chief Commercial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 10,000 shares Expires 2032-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023. F7 · derivative.exercise_date: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.